Evaluating the combination of Oncotype DX and Neutrophil/Leukocyte Ratios as prognostic indicators of chemotherapy response in breast cancer. (360G-Wellcome-207246_Z_17_Z)

This research will study the effect of the individual’s immune system on their reoccurrence of breast cancer after chemotherapy. This would be a correlation between the Neutrophil to Lymphocyte Ratio (NLR) and the Oncotype Dx score. Previous research (unpublished) has demonstrated the significance of the NRL in predicting breast cancer outcomes in HER 2 overexpressing and Luminal B breast cancer (accounting for approx. 20% of all breast cancers). We will extend our previous research to include all four cancer subtypes (Luminal A and Triple negative breast cancer). We aim to compare the immune system’s reaction to chemotherapy across all four cancer subtypes. A key goal is to determine if NLR predicts outcome or survival in Luminal A or TNBC. A further key goal is to determine if there is any predictive value of combining the NLR with Oncotype scores (in relevant cases).

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 0
Applicant Surname Ni Mhaonaigh
Approval Committee Internal Decision Panel
Award Date 2017-04-27T00:00:00+00:00
Financial Year 2016/17
Grant Programme: Title Vacation Scholarships
Internal ID 207246/Z/17/Z
Lead Applicant Miss Niamh Ni Mhaonaigh
Partnership Value 0
Planned Dates: End Date 2017-08-04T00:00:00+00:00
Planned Dates: Start Date 2017-06-05T00:00:00+00:00
Recipient Org: Country Ireland
Region Ireland